Skip to main content
Premium Trial:

Request an Annual Quote

PolyGenyx Snares $1M SBIR Help for Haplotyping

NEW YORK, June 25 -- PolyGenyx, a Worcester, Mass., haplotyping startup, announced today that it has received a $997,673 Phase II Small Business Innovative Research grant from the National Human Genome Research Institute.

The company plans to use the grant, which spans two years, on development of HaploScan, its haplotyping platform, and develop haplotyping assays for the platform that can be commercialized.

The technology, based on the Luminex 100 microbead system, requires less than one hour for users to haplotype samples that involve two-SNP or multi-SNP haplotpyes.

The company adapted the technology for the Luminex platform in a previous Phase 1 SBIR grant. HapScan can also be automated, according to PolyGenyx, using standard liquid handling robots. The company is developing software for the automation of haplotype scoring.

 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.